Electronic Health Records Poised to Benefit Healthcare with New Partnerships

Electronic Health Records (EHR) Big Tech is teaming up with big tech to transform healthcare.

Three giants in the electronic health record industry, Epic, Meditech, and Oracle Cerner, recently announced agreements with several Big Tech organizations and some tech startups to provide improved offerings to healthcare organizations.

Epic entered into an agreement with Google Cloud, enabling health systems to migrate their EHRs to the cloud. Meditech entered a similar partnership with Google. In addition, Meditech is integrating its platform with digital care company SeamlessMD.

Oracle Cerner partnered with life sciences company Labcorp to manage hospital-based laboratories in 10 states. This partnership allows Labcorp to standardize and optimize workflows for better efficiency and support information sharing.

If overcoming healthcare challenges, and improving the EHR process is the goal, then these announcements are sure to move the industry in a positive direction. David Kemp, Healthcare Lead at MarketScale, shares the industry’s enthusiasm about the partnerships.

David’s Thoughts

“So if you’ve been around healthcare long enough, you know interoperability is a big challenge. Exchanging data between systems is important for a lot of reasons, mainly to integrate that data to make better, smarter decisions for the patient to improve the patient outcome. But interoperability has always been a challenge, and so exciting news here is that Epic, arguably the largest electronic health record provider in the space is launching The Connection Hub on January 9th. It’s essentially a website where other vendors can prove and be documented or attain interoperability certification through Epic. This will allow providers, and other Epic users to come on and see what vendors they should use to maybe fill in some gaps or some holes in their functionality.

So I think this is a good step for the industry. I think it’s a good step for providers to be able to have access to that information and make smarter, easier, quicker decisions on what vendors to consider when evaluating during the sales process. But it’ll be interesting to see what Epic does with this data.

Now they get to see who has that integration built out in the space, what maybe features or functionalities they’re able to provide to the provider community, and maybe they start making decisions on what next features and functionalities they want to add to the Epic system. Ultimately, I think it’s a benefit for everybody.

It allows those vendors to get exposure to the providers that they want to work with. It gives the information to the providers when looking to fill gaps in their features and functionality, but Epic because they own the data might benefit the most. Overall, I think it’s a positive step in the right direction and uh, we’ll see what it really looks like on January 9th when Epic launches the Connection Hub.”

Article by James Kent

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More